General

Pronunciation:
nay-doe-lole


Trade Name(s)

  • Corgard
  • Syn-Nadolol Canadian Tradename

Ther. Class.
antianginals
antihypertensives

Pharm. Class.
beta blockers

Indications

  • Management of hypertension.
  • Management of angina pectoris.

Unlabeled Use(s):

  • Arrhythmias.
  • Migraine prophylaxis.
  • Tremors (essential, lithium-induced, parkinsonian).
  • Aggressive behavior.
  • Antipsychotic-associated akathisia.
  • Situational anxiety.
  • Esophageal varices.
  • Reduction of intraocular pressure.

Action

Blocks stimulation of beta1 (myocardial) and beta2 (pulmonary, vascular, and uterine) receptor sites.

Therapeutic Effect(s):

Decreased heart rate and BP.

Pharmacokinetics

Absorption: 30% absorbed after oral administration.

Distribution: Minimal penetration of the CNS. Crosses the placenta and enters breast milk.

Metabolism and Excretion: 70% excreted unchanged by the kidneys.

Half-life: 10–24 hr (↑ in renal impairment).

TIME/ACTION PROFILE (anithypertensive effects)

ROUTEONSETPEAKDURATION
PO†up to 5 days6–9 days24 hr
†With chronic dosing.

Contraindication/Precautions

Contraindicated in:

  • Uncompensated HF;
  • Pulmonary edema;
  • Cardiogenic shock;
  • Bradycardia or heart block.

Use Cautiously in:

  • Renal impairment (CCr <50 mL/min);
  • Hepatic impairment;
  • Pulmonary disease (including asthma);
  • Diabetes mellitus (may mask signs of hypoglycemia);
  • Thyrotoxicosis (may mask symptoms);
  • Patients with a history of severe allergic reactions (intensity of reactions may be ↑);
  • OB: Crosses the placenta and may cause fetal/neonatal bradycardia, hypotension, hypoglycemia, or respiratory depression;
  • Lactation:Pedi: Safety not established;
  • Geri: ↑ sensitivity to beta blockers; initial dose ↓ recommended.

Adverse Reactions/Side Effects

CNS: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nightmares

EENT: blurred vision, dry eyes, nasal stuffiness

Resp: bronchospasm, wheezing

CV: ARRHYTHMIAS, BRADYCARDIA, HF, PULMONARY EDEMA, orthostatic hypotension, peripheral vasoconstriction

GI: constipation, diarrhea, nausea

GU: erectile dysfunction, ↓ libido

Derm: itching, rashes

Endo: hyperglycemia, hypoglycemia

MS: arthralgia, back pain, muscle cramps

Neuro: paresthesia

Misc: drug-induced lupus syndrome

* CAPITALS indicate life-threatening.
Underline indicate most frequent.

Interactions

Drug-Drug

  • General anesthesia, IV phenytoin, diltiazem, and verapamil may cause additive myocardial depression.
  • Additive bradycardia may occur with digoxin.
  • Additive hypotension may occur with other antihypertensives, acute ingestion of alcohol, or nitrates.
  • Concurrent use with amphetamines, cocaine, ephedrine, epinephrine, norepinephrine, phenylephrine, or pseudoephedrine may result in unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia).
  • Concurrent use with clonidine ↑ hypotension and bradycardia.
  • Concurrent thyroid administration may ↓ effectiveness.
  • May alter the effectiveness of insulins or oral hypoglycemic agents (dosage adjustments may be necessary).
  • May ↓ the effectiveness of theophylline.
  • May ↓ the effects of dopamine or dobutamine.
  • Use cautiously within 14 days of MAO inhibitor therapy (may result in hypertension).
  • Concurrent NSAIDs may ↓ antihypertensive action.

Route/Dosage

PO: (Adults) Antianginal– 40 mg once daily initially; may ↑ by 40–80 mg/day q 3–7 days as needed (up to 240 mg/day). Antihypertensive– 40 mg once daily initially; may ↑ by 40–80 mg/day q 7 days as needed (up to 320 mg/day).

Renal Impairment
PO: (Adults) CCr 31–50 mL/min– ↑ dosing interval to 24–36 hr; CCr 10–30 mL/min– ↑ dosing interval to 24–48 hr; CCr <10 mL/min– ↑ dosing interval to 40–60 hr.

Availability (generic available)

Tablets: 20 mg, 40 mg, 80 mg

In Combination with:bendroflumethiazide (Corzide). See combination drugs.

Assessment

  • Monitor BP and pulse frequently during dose adjustment and periodically during therapy. Assess for orthostatic hypotension when assisting patient up from supine position.
  • Monitor intake and output ratios and daily weight. Assess patient routinely for evidence of fluid overload (peripheral edema, dyspnea, rales/crackles, fatigue, weight gain, jugular venous distention).
  • Hypertension: Check frequency of refills to determine compliance.
  • Angina: Assess frequency and characteristics of angina periodically during therapy.

Lab Test Considerations: May cause increased BUN, serum lipoprotein, potassium, triglyceride, and uric acid levels.

  • May cause increased ANA titers.
  • May cause increase in blood glucose levels.

Toxicity Overdose:

Monitor patients receiving beta blockers for signs of overdose (bradycardia, severe dizziness or fainting, severe drowsiness, dyspnea, bluish fingernails or palms, seizures). Notify physician or other health care professional immediately if these signs occur.

Potential Diagnoses

Implementation

  • Discontinuation of concurrent clonidine should be done gradually, with beta blocker discontinued first; then, after several days, discontinue clonidine.
  • PO: Take apical pulse before administering. If <50 bpm or if arrhythmia occurs, withhold medication and notify physician or other health care professional.
    • May be administered with food or on an empty stomach.
    • Tablets may be crushed and mixed with food.

Patient/Family Teaching

  • Instruct patient to take medication exactly as directed, at the same time each day, even if feeling well; do not skip or double up on missed doses. Take missed doses as soon as possible up to 8 hr before next dose. Abrupt withdrawal may precipitate life-threatening arrhythmias, hypertension, or myocardial ischemia.
  • Advise patient to ensure that enough medication is available for weekends, holidays, and vacations. A written prescription may be kept in wallet for emergencies.
  • Teach patient and family how to check pulse and BP. Instruct them to check pulse daily and BP biweekly. Advise patient to hold dose and contact health care professional if pulse is <50 bpm or if BP changes significantly.
  • May cause drowsiness or dizziness. Caution patients to avoid driving or other activities that require alertness until response to the drug is known.
  • Advise patients to make position changes slowly to minimize orthostatic hypotension, especially during initiation of therapy or when dose is increased.
  • Caution patient that this medication may increase sensitivity to cold.
  • Instruct patient to consult health care professional before taking any OTC medications, especially cold preparations, concurrently with this medication.
  • Patients with diabetes should closely monitor blood glucose, especially if weakness, malaise, irritability, or fatigue occurs. Medication may mask some signs of hypoglycemia, but dizziness and sweating may still occur.
  • Advise patient to notify health care professional if slow pulse, difficulty breathing, wheezing, cold hands and feet, dizziness, confusion, depression, rash, fever, sore throat, unusual bleeding, or bruising occurs.
  • Instruct patient to inform health care professional of medication regimen before treatment or surgery.
  • Advise patient to carry identification describing disease process and medication regimen at all times.
  • Hypertension: Reinforce the need to continue additional therapies for hypertension (weight loss, sodium restriction, stress reduction, regular exercise, moderation of alcohol consumption, and smoking cessation). Medication controls but does not cure hypertension.
  • Angina: Caution patient to avoid overexertion with decrease in chest pain.

Evaluation/Desired Outcomes

  • Decrease in BP.
  • Reduction in frequency of angina.
    • Increase in activity tolerance. May require up to 5 days before therapeutic effects are seen.
nadolol is a sample topic from the Davis's Drug Guide.

To view other topics, please or purchase a subscription.

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Learn more.

Citation

* When formatting your citation, note that all book, journal, and database titles should be italicized* Article titles in AMA citation format should be in sentence-case
TY - ELEC T1 - nadolol ID - 51524 A1 - Quiring,Courtney, AU - Sanoski,Cynthia A, AU - Vallerand,April Hazard, BT - Davis's Drug Guide UR - https://peds.unboundmedicine.com/pedscentral/view/Davis-Drug-Guide/51524/all/nadolol PB - F.A. Davis Company ET - 16 DB - Pediatrics Central DP - Unbound Medicine ER -